The corresponding [68Ga]NOTA-AMBS-Ahx-conjugated analog (entry 14, Table 1; Figure 3) shows excellent CXCR4-targeting in vitro and in vivo, and despite lower absolute uptake in Daudi xenografts (ca. 50% of the uptake found for [68Ga]Pentixafor [102]), improved tumor/background ratios due to particularly low background accumulation [80]. Here, CXCR4 is linked to neoplasm.